Le Lézard
Classified in: Health, Science and technology
Subjects: Event, Webcast

Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day


Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's management will participate in a fireside chat event during Citi's 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024, at 2:30 PM Eastern Time (11:30 AM Pacific Time).

A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad's website at bio-rad.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.


These press releases may also interest you

at 03:38
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024
Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima increased to 7 months. January ? March...

at 03:05
EAACI Congress 2024: Innovation and Advances in Allergy Treatment
The European Academy of Allergy and Clinical...

at 03:00
BioWorld by Clarivate Explores the Future of CAR T Therapy in Mainland China in Special Report
BioWorldtm published by  Clarivate Plc , a leading global provider of transformative intelligence, explores the growing investment in CAR T therapy development in mainland China in a new series titled "China's CAR T market comes of age." The report...

at 03:00
SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab
SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company developing emactuzumab...

at 03:00
Medit launches the revolutionary i900, an intraoral scanning system set to redefine the scanning experience for dental clinics worldwide
Medit (www.medit.com), a leading provider of dental 3D scanners and digital dentistry solutions, introduces the Medit i900 intraoral scanner, setting a new standard for speed, accuracy, and comfort. "The brilliance of the Medit i900 lies in its...

at 02:30
111 to Announce First Quarter 2024 Unaudited Financial Results on May 23, 2024 - Conference Call to Follow
111, Inc. ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for...

More news about Health...


News published on and distributed by: